Key result
Estroprogestin replacement therapy increases end-diastolic index by ~23% over no therapy at 6 months.
Why the study?
The study was motivated by the need to evaluate possible variations in cardiac hemodynamic parameters related to natural changes of ovarian estrogen production in postmenopausal women.
Does estroprogestin replacement therapy improve cardiac hemodynamic parameters in healthy postmenopausal women?
RCT (n=40)
randomized
Does estroprogestin replacement therapy improve cardiac hemodynamic parameters in healthy postmenopausal women?
Absolute Event Rate: 70.27% vs 57.13%
p-value: p=< 0.05
A 6-month course of estroprogestin replacement therapy significantly improves cardiac performance and reduces systemic vascular resistance in healthy postmenopausal women.
No takes yet. Share an insight, caveat, or question.
ERT may improve hemodynamics after 6 months; hypothesis-generating for CV effects, needs larger outcome trials.
Gallinelli et al. (1999) conducted an RCT in Postmenopausal (n=40). Estroprogestin replacement therapy (ERT) vs. No ERT was evaluated on Mean end-diastolic index (p=< 0.05). Estroprogestin replacement therapy for 6 months significantly improved mean end-diastolic index compared to no therapy (70.27 vs. 57.13 mL/m2; p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: